Anti-NS1 mAbs could be developed alone or in combination with anti-envelope protein antibodies (the latter possibly engineered to lack Fc interactions to avoid ADE) for prevention against ZIKV infection and congenital disease. The gene discussed is ERVW-1; the disease is Zika virus infectious disease.